Aurinia Pharmaceuticals Inc (AUPH)

[CoolG73]

In the AURA trial, The Mean duration of CR for VCS was 17.5 weeks vs 9.4 weeks for Placebo, which means we have twice the CR duration than SoC . The change in the low prednisone condition (<10 mg / day to achieve CR) from week 16 thru 24 ( in AURA) to 44 thru 52 (in AURORA) will have a significant impact on the Placebo arm since they won't be able to increase the dose in the last 9 weeks of the trial if a patient relapsed ( 9 weeks is also the same number of weeks that a placebo CR lasts). it could reduce the placebo CR % significantly while not impacting the VCS arm who has a double duration for its CR.